Multiple Myeloma Interview with David H. Vesole, MD, PhD, at ASH 2011 HD

At the American Society of Hematology (ASH) 2011, David H. Vesole, MD, PhD, Co-Chief, Myeloma Division Director, Myeloma Research at the John Theurer Cancer Center at the Hackensack University Medical Center, discusses the final results of a frontline phase 1/2 study of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) in multiple myeloma, as well as the phase 1b/2 study of prolonged infusion carfilzomib in patients with relapsed and/or refractory multiple myeloma.